Cargando…

The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma

BACKGROUND: The distinction between combined hepatocellular-cholangiocarcinoma (cHCC-CC) and hepatocellular carcinoma (HCC) before the operation has an important clinical significance for optimizing the treatment plan and predicting the prognosis of patients. Magnetic resonance imaging (MRI) has bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Lun, Zhang, ChenCai, Yu, Xian, Zhang, Ling, Feng, YaYuan, Wu, YuXian, Xia, JinJu, Chen, Xue, Zhang, RuiPing, Zhang, Juan, Jia, Ningyang, Zhang, SiSi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499763/
https://www.ncbi.nlm.nih.gov/pubmed/36157231
http://dx.doi.org/10.1155/2022/4691172
_version_ 1784795070515380224
author Lu, Lun
Zhang, ChenCai
Yu, Xian
Zhang, Ling
Feng, YaYuan
Wu, YuXian
Xia, JinJu
Chen, Xue
Zhang, RuiPing
Zhang, Juan
Jia, Ningyang
Zhang, SiSi
author_facet Lu, Lun
Zhang, ChenCai
Yu, Xian
Zhang, Ling
Feng, YaYuan
Wu, YuXian
Xia, JinJu
Chen, Xue
Zhang, RuiPing
Zhang, Juan
Jia, Ningyang
Zhang, SiSi
author_sort Lu, Lun
collection PubMed
description BACKGROUND: The distinction between combined hepatocellular-cholangiocarcinoma (cHCC-CC) and hepatocellular carcinoma (HCC) before the operation has an important clinical significance for optimizing the treatment plan and predicting the prognosis of patients. Magnetic resonance imaging (MRI) has been widely used in the preoperative diagnosis and evaluation of primary liver malignant tumors. PURPOSE: The aim is to study the value of preoperative clinical data and enhanced MRI in the differential diagnosis of HCC and cHCC-CC and obtain independent risk factors for predicting cHCC-CC. Study type. Retrospective. Population. The clinical and imaging data of 157 HCC and 59 cHCC-CC patients confirmed by pathology were collected. Field Strength/Sequence. 1.5T; cross-sectional T1WI (gradient double echo sequence); cross-sectional T2WI (fast spin echo sequence, fat suppression); enhancement (3D LAVA technology). Assessment. The differences between the HCC and cHCC-CC patients were compared. Statistic Tests. Using the t-test, chi-square test, and logistic regression analysis, P < 0.05 was considered statistically significant. RESULT: 1. CHCC-CC was more likely to show multiple lesions than HCC (28.81% vs. 10.83%, P = 0.001) and more prone to microvascular invasion (MVI) (36.31% vs. 61.02%, P < 0.001). However, HCC had a higher incidence of liver cirrhosis than cHCC-CC (50.85% vs. 72.61%, P = 0.003). 2. The incidence of nonsmooth margin was higher in the cHCC-CC group (84.75% vs. 52.23%, P < 0.001). The incidence of peritumor enhancement in the arterial phase was higher in the cHCC-CC group (11.46% vs. 62.71%, P < 0.001) 3. According to the multivariate analysis, arterial peritumor enhancement (OR = 8.833,95%CI:4.033,19.346, P < 0.001) was an independent risk factor for cHCC-CC (P < 0.001)). It had high sensitivity (62.71%) and specificity (88.54%) in the diagnosis of cHCC-CC. Date Conclusions. Liver cirrhosis and the imaging findings of GD-DTPA-enhanced MRI are helpful for the differential diagnosis of HCC and cHCC-CC. In addition, the imaging sign of peritumoral enhancement in the arterial phase has high sensitivity and specificity for the diagnosis of cHCC-CC.
format Online
Article
Text
id pubmed-9499763
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-94997632022-09-23 The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma Lu, Lun Zhang, ChenCai Yu, Xian Zhang, Ling Feng, YaYuan Wu, YuXian Xia, JinJu Chen, Xue Zhang, RuiPing Zhang, Juan Jia, Ningyang Zhang, SiSi J Oncol Research Article BACKGROUND: The distinction between combined hepatocellular-cholangiocarcinoma (cHCC-CC) and hepatocellular carcinoma (HCC) before the operation has an important clinical significance for optimizing the treatment plan and predicting the prognosis of patients. Magnetic resonance imaging (MRI) has been widely used in the preoperative diagnosis and evaluation of primary liver malignant tumors. PURPOSE: The aim is to study the value of preoperative clinical data and enhanced MRI in the differential diagnosis of HCC and cHCC-CC and obtain independent risk factors for predicting cHCC-CC. Study type. Retrospective. Population. The clinical and imaging data of 157 HCC and 59 cHCC-CC patients confirmed by pathology were collected. Field Strength/Sequence. 1.5T; cross-sectional T1WI (gradient double echo sequence); cross-sectional T2WI (fast spin echo sequence, fat suppression); enhancement (3D LAVA technology). Assessment. The differences between the HCC and cHCC-CC patients were compared. Statistic Tests. Using the t-test, chi-square test, and logistic regression analysis, P < 0.05 was considered statistically significant. RESULT: 1. CHCC-CC was more likely to show multiple lesions than HCC (28.81% vs. 10.83%, P = 0.001) and more prone to microvascular invasion (MVI) (36.31% vs. 61.02%, P < 0.001). However, HCC had a higher incidence of liver cirrhosis than cHCC-CC (50.85% vs. 72.61%, P = 0.003). 2. The incidence of nonsmooth margin was higher in the cHCC-CC group (84.75% vs. 52.23%, P < 0.001). The incidence of peritumor enhancement in the arterial phase was higher in the cHCC-CC group (11.46% vs. 62.71%, P < 0.001) 3. According to the multivariate analysis, arterial peritumor enhancement (OR = 8.833,95%CI:4.033,19.346, P < 0.001) was an independent risk factor for cHCC-CC (P < 0.001)). It had high sensitivity (62.71%) and specificity (88.54%) in the diagnosis of cHCC-CC. Date Conclusions. Liver cirrhosis and the imaging findings of GD-DTPA-enhanced MRI are helpful for the differential diagnosis of HCC and cHCC-CC. In addition, the imaging sign of peritumoral enhancement in the arterial phase has high sensitivity and specificity for the diagnosis of cHCC-CC. Hindawi 2022-09-15 /pmc/articles/PMC9499763/ /pubmed/36157231 http://dx.doi.org/10.1155/2022/4691172 Text en Copyright © 2022 Lun Lu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lu, Lun
Zhang, ChenCai
Yu, Xian
Zhang, Ling
Feng, YaYuan
Wu, YuXian
Xia, JinJu
Chen, Xue
Zhang, RuiPing
Zhang, Juan
Jia, Ningyang
Zhang, SiSi
The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma
title The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma
title_full The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma
title_fullStr The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma
title_full_unstemmed The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma
title_short The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma
title_sort value of contrast-enhanced magnetic resonance imaging enhancement in the differential diagnosis of hepatocellular carcinoma and combined hepatocellular cholangiocarinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499763/
https://www.ncbi.nlm.nih.gov/pubmed/36157231
http://dx.doi.org/10.1155/2022/4691172
work_keys_str_mv AT lulun thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT zhangchencai thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT yuxian thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT zhangling thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT fengyayuan thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT wuyuxian thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT xiajinju thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT chenxue thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT zhangruiping thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT zhangjuan thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT jianingyang thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT zhangsisi thevalueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT lulun valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT zhangchencai valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT yuxian valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT zhangling valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT fengyayuan valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT wuyuxian valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT xiajinju valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT chenxue valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT zhangruiping valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT zhangjuan valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT jianingyang valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma
AT zhangsisi valueofcontrastenhancedmagneticresonanceimagingenhancementinthedifferentialdiagnosisofhepatocellularcarcinomaandcombinedhepatocellularcholangiocarinoma